Brief: Pharmabcine Announces Safety Approval For 1st dose Cohort In Phase 1A/B Clinical Trial Of Pmc-309
08/07/2024 18:45
July 8 (Reuters) - PharmAbcine Inc 208340.KQ :
* PHARMABCINE ANNOUNCES SAFETY APPROVAL FOR THE FIRST DOSE
COHORT
IN PHASE 1A/B CLINICAL TRIAL OF PMC-309 IN PATIENTS WITH
ADVANCED OR METASTATIC SOLID TUMORS
* PHARMABCINE - PMC-309 RECEIVES SAFETY APPROVAL FOR FIRST
DOSE
COHORT (0.2MG/KG), AND SECOND DOSE COHORT (0.5MG/KG) IS
CURRENTLY UNDERWAY IN AUSTRALIA.
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on PharmAbcine
See all newsBrief: Pharmabcine Announces Safety Approval For 1st dose Cohort In Phase 1A/B Clinical Trial Of Pmc-309
Brief: Pharmabcine To Conduct Capital Increase Of 26 Billion Won For Operational Funds
Brief: Pharmabcine To Conduct Capital Increase Of 3.7 Billion Won For Operational Funds
Brief: Pharmabcine To Conduct Capital Increase Of 4.7 Billion Won For Operational Funds
Brief: PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration